Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Perspectum · NCT04054310
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–75 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Not applicable
- Target enrollment
- 225
- US sites recruiting
- 6
- Study start
- August 5, 2020
- Record last updated
- May 19, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 \& F≥2 from those without.
Being studied: Liver Multi Scan
Conditions: NASH - Nonalcoholic Steatohepatitis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Male and Female subjects aged between 18 and 75 years old
- Ability to understand and sign a written informed consent forms
- Patients scheduled to undergo a standard of care diagnostic liver biopsy as follows
- Percutaneous biopsy with a 16 gauged needle passed into the right lobe
- Trans-jugular biopsy with an 18 gauged needle passed into the right lobe
- Patients who are suspected of having NAFLD, who are being considered for treatment, and presenting with two or more of the following risk factors for NASH
- Elevated liver enzymes (ALT≥40)
- BMI≥25kG/m\^2
- Hypertension
- Type II diabetes
- Dyslipidameia
- Low High-density lipoprotein (HDL) (\<40mg/dl in men or \<50mg/dl in women)
- Hypertriglyceridemia (≥150mg/dl)
- Hypercholestrolemia (≥200mg/dl)
- Triglycerides (TG)/HDL>5.0
Exclusion Criteria
- Prior histopathological diagnosis of NASH
- Inability to undergo a liver biopsy
- Prior or planned liver transplantation
- Patient scheduled to undergo a laparoscopic or wedge liver biopsy or biopsy taken from the left lobe
- Participation in an investigational new drug (IND) trial in the 30 days before enrolment
- Other known causes of chronic liver disease based on clinical criteria at the study site such as the following:
- Alcoholic liver disease
- Primary biliary cirrhosis
- Primary sclerosing cholangitis
- Autoimmune Hepatitis
- Wilson's disease, hemochromatosis, iron overload
- Alpha/1/Antitrypsin (A1AT) deficiency
- HCV, HBV
- History or diagnosis of cirrhosis and or hepatic decompensation including ascites, hepatic encephalopathy or variceal bleeding
- Clinically relevant drug or alcohol abuse within 12 months of screening
- Any contradiction or significant limitation to MRI scanning
- Claustrophobia preventing MR imaging (requires 15-30 minutes in scanning)
- Pacemaker or another implanted device
- Metal in body (such as an aneurysm clip) that might produce artefacts on abdominal MRI or might be adversely impacted by a high magnetic field
- Inability to lie flat, remain still or briefly hold breath as necessary during MR imaging
- Medical condition likely to produce significant hypervolemia like congestive heart failure
- Severe obesity complicating positioning in MR scanner
- Weight reduction surgery within 3 years
- Concomitant medical illnesses per investigators discretion (such as HIV infection, recent major surgery, uncontrolled heart disease, concurrent infection or fever of unknown origin, illicit drug use, cancer
- Clinically significant medical or psychiatric condition considered a high risk participation in an investigational study
- Failure to give informed consent
Recruiting US locations
Arizona Liver Health
Chandler, AZ 85224
Site contact: David Rios, MD · drios@azliver.com
RUSH University Medical Center
Chicago, IL 60612
Site contact: Lelani Fetrow, BSN · Lelani_C_Fetrow@rush.edu
Indiana University Health
Indianapolis, IN 46202
Site contact: Sreemala Murthy, BSc · srmurthy@iu.edu
Icahn School of Medicine at Mount Sinai
New York, NY 10029
Site contact: Elianna Sanchez · elianna.sanchez@mssm.edu
University of Virginia
Charlottesville, VA 22908
Site contact: Cheree Denbee · cjd4a@hscmail.mcc.virginia.edu
Virginia Common wealth University
Richmond, VA 23284
Site contact: Arun Sanyal, MD · 8048284060 · arun.sanyal@vcuhealth.org
Study contacts (from the official record)
- Cayden Beyer · 01865655343 · cayden.beyer@perspectum.com
Similar studies in Arizona
All nutrition & metabolism studies in Arizona →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Developing Biomarkers of Dietary Intake: Dose Dependent Measurement of Sugar Intake
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Location
- Phoenix, AZ
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteers
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Cleerly, Inc.
- Location
- Chandler, AZ + 121 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Hoffmann-La Roche
- Location
- Chandler, AZ + 121 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Hoffmann-La Roche
- Location
- Chandler, AZ + 112 other US sites
- Eligibility basics
- Ages 18–75